Altre lingue HBM Holdings Limited

Azioni

2142

KYG4403H1002

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:35 19/04/2024			Variaz. 5gg	Var. 1 gen.
1,04 ^HKD	-2,80%		-7,96%	-46,39%

02/04	HBM Holdings torna alla redditività nel 2023	MT
28/03	HBM Holdings Limited riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

HBM Holdings Returns to Profitability in 2023	02/04
Harbour BioMed Reports Full Year 2023 Financial Results	28/03
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	27/02
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	24/01
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	24/01
HBM to Swing to 2023 Profit	19/01
Harbour BioMed Announces Positive Profit Alert	19/01
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	19/01
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	19/12
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	15/12
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	15/12
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	01/12
HBM Holdings Limited Announces Executive Changes	19/10/23
HBM Swings to Profit in H1; Shares Up 6%	29/08/23
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US	29/08/23
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	28/08/23
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08/08/23
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue HBM Holdings Limited

Azioni

2142

KYG4403H1002

Altre lingue

Filtri